Glia protects neurons against extracellular human neuromelanin

Neurodegenerative Diseases

Volumn 4, Issue 2-3, 2007, Pages 218-226

  Depboylu, Candan ^a   Matusch, Andreas ^b   Tribl, Florian ^c   Zoriy, Myroslav ^b   Michel, Patrick P ^d,e   Riederer, Peter ^c   Gerlach, Manfred ^c   Becker, Sabine ^b   Oertel, Wolfgang H ^a   Höglinger, Günter U ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Mass spectrometry; Mitochondrial complex I; Neuromelanin; Neuronal cell culture; Reactive oxygen species

Indexed keywords

FLUOROCHROME; IRON; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROMELANIN; REACTIVE OXYGEN METABOLITE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GLIA; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN PURIFICATION; RAT;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELANINS; MESENCEPHALON; MICROTUBULE-ASSOCIATED PROTEINS; NEUROGLIA; NEURONS; PARKINSON DISEASE; POSTMORTEM CHANGES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 34347247677     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000101846     Document Type: Article

References (38)

1. Youdim MB, Ben-Shachar D, Riederer P: The enigma of neuromelanin in Parkinson's disease substantia nigra. J Neural Transm 1994;43(suppl):113-122.
2. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P: Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res 2003;5:35-44.
3. Zecca L, Zucca FA, Wilms H, Sulzer D: Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580.
4. Hirsch E, Graybiel AM, Agid YA: Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
5. Damier P, Hirsch EC, Agid Y, Graybiel AM: The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122:1437-1448.
6. Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M: Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 2000;75:2583-2589.
7. Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D: Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001;76:1766-1773.
8. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R: Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003;17:500-502.
9. Tribl F, Gerlach M, Marcus K, Asan E, Tatschner T, Arzberger T, Meyer HE, Bringmann G, Riederer P: 'Subcellular proteomics' of neuromelanin granules isolated from the human brain. Mol Cell Proteomics 2005;4:945-957.
10. Kawamoto JC, Barrett JN: Cryopreservation of primary neurons for tissue culture. Brain Res 1986;384:84-93.
11. Höglinger GU, Carrard G, Michel PP, Friguet B, Hirsch EC: Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 2003;86:1297-1307.
12. Zecca L, Tampellini E, Rizzio E, Giaveri G, Gallorini M: The determination of iron and other metals by INNA in cortex, cerebellum and putamen of human brain and in their neuromelanins. J Radioanalyt Nucl Chem 2001;248:129-131.
13. Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MBH, Riederer P, Ben-Shachar D: Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 2003;66:489-494.
14. Bridelli MG, Tampellini D, Zecca L: The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett 1999;457:18-22.
15. Zecca L, Mecacci C, Seraglia R, Parati E: The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1992;1138:6-10.
16. Loschen G, Flohe L, Chance B: Respiratory chain linked H(2)O(2) production in pigeon heart mitochondria. FEBS Lett 1971;18:261-264.
17. Boveris A, Oshino N, Chance B: The cellular production of hydrogen peroxide. Biochem J 1972;128:617-630.
18. Liu Y, Fiskum G, Schubert D: Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002;80:780-787.
19. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;i:1269.
20. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145.
21. Kropf AJ, Bunker BA, Eisner M, Moss SC, Zecca L, Stroppolo A, Crippa PR: X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues. Biophys J 1998;75:3135-3142.
22. Dzierzega-Lecznar A, Kurkiewicz S, Stepien K, Chodurek E, Wilczok T, Arzberger T, Riederer P, Gerlach M: GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra. J Am Soc Mass Spectrom 2004;15:920-926.
23. Ostergren A, Svensson AL, Lindquist NG, Brittebo EB: Dopamine melanin-loaded PC12 cells: a model for studies on pigmented neurons. Pigment Cell Res 2005;18:306-314.
24. Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, Halliday G, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL: Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 2005;95:599-608.
25. Bachur NR, Gordon SL, Gee MV, Kon H: NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979;76:954-957.
26. Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, Bronson RT, Ackerman SL: The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002;419:367-374.
27. Lipton SA, Bossy-Wetzel E: Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147-150.
28. Wakamatsu K, Fujikawa K, Zucca F, Zecca L, Ito S: The structure of neuromelanin as studied by chemical degradative methods. J Neurochem 2003;86:1015-1023.
29. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA: The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004;101:9843-9848.
30. Zecca L, Shima T, Stroppolo A, Goj C, Battiston GA, Gerbasi R, Sarna T, Swartz HM: Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996;73:407-415.
31. Rao KS, Hegde ML, Anitha S, Musicco M, Zucca FA, Turro NJ, Zecca L: Amyloid beta and neuromelanin - toxic or protective molecules? The cellular context makes the difference. Prog Neurobiol 2006;78:364-373.
32. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57-69.
33. Aimi Y, McGeer PL: Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinson Rel Disord 1996;2:69-74.
34. Ishida Y, Nagai A, Kobayashi S, Kim SU: Up-regulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 2006;65:66-77.
35. Desagher S, Glowinski J, Premont J: Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996;16:2553-2562.
36. Dhandapani KM, Hadman M, De Sevilla L, Wade MF, Mahesh VB, Brann DW: Atrocyte protection of neurons: role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway. J Biol Chem 2003;278:43329-43339.
37. Saavedra A, Baltazar G, Santos P, Carvalho CM, Duarte EP: Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 2006;23:533-542.
38. Michel PP, Marien M, Ruberg M, Colpaert F, Agid Y: Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J Neurochem 1999;72:2074-2082.